These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 5686327)

  • 41. ["Depressive shift" in the course of treatment of schizophrenic psychosis with phenothiazines].
    Bohacek N
    Neuropsihijatrija; 1967; 15(1):97-103. PubMed ID: 5191808
    [No Abstract]   [Full Text] [Related]  

  • 42. An uncontrolled clinical study with piperacetazine in the maintenance treatment of chronic schizophrenic patients.
    Amin MM; Brahm E; Ban TA; Lehmann HE
    Psychopharmacol Bull; 1977 Jul; 13(3):10-1. PubMed ID: 18753
    [No Abstract]   [Full Text] [Related]  

  • 43. [Relationship between the effect of phenothiazine and butyrophenone and the glutamine level in the blood of schizophrenics].
    Kluge H; Wieczorek V; Greger J; Hemke G; Hankowitz M
    Wien Z Nervenheilkd Grenzgeb; 1968; 26(2):191-5. PubMed ID: 4239986
    [No Abstract]   [Full Text] [Related]  

  • 44. A standard-controlled clinical study with propericiazine in schizophrenic patients.
    Ananth JV; Ban TA
    Psychopharmacol Bull; 1977 Jul; 13(3):19-20. PubMed ID: 18754
    [No Abstract]   [Full Text] [Related]  

  • 45. Nicotinic acid as adjuvant therapy in newly admitted schizophrenic patients.
    Ramsay RA; Ban TA; Lehmann HE; Saxena BM; Bennett J
    Can Med Assoc J; 1970 May; 102(9):939-42. PubMed ID: 4157149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Specifc electroencephalographic changes with pentothal activation in psychotic states.
    GOLDMAN D
    Electroencephalogr Clin Neurophysiol; 1959 Nov; 11():657-67. PubMed ID: 13850678
    [No Abstract]   [Full Text] [Related]  

  • 47. A comparison of phenothiazines in managing aggressive episodes in schizophrenic patients.
    Simeon J; Wadud A; Itil T
    Hosp Community Psychiatry; 1975 Sep; 26(9):574. PubMed ID: 238907
    [No Abstract]   [Full Text] [Related]  

  • 48. Altered sensitivity to centrally active drugs following lobotomy.
    Itil TM; Holden JM; Keskiner A; Fink M
    Recent Adv Biol Psychiatry; 1966; 9():157-69. PubMed ID: 4878855
    [No Abstract]   [Full Text] [Related]  

  • 49. Urinary metabolites of 10-(3'-(4"-methyl-piperazinyl)-propyl)-phenothiazine (perazine) in psychiatric patients. II. Individual metabolite patterns and their changes in the course of treatment.
    Kanig K; Breyer U
    Psychopharmacologia; 1969; 14(3):211-20. PubMed ID: 5351861
    [No Abstract]   [Full Text] [Related]  

  • 50. Beginning research: care of the schizophrenic patient.
    Scott E; Sharma SK; Temple K
    Nurs Times; 1977 May; 73(20):740-1. PubMed ID: 866224
    [No Abstract]   [Full Text] [Related]  

  • 51. Carphenazine in the treatment of schizophrenic psychoses. Controlled clinical trial.
    Vinar O; Formánková M; Taussigová D; Růzicka S
    Act Nerv Super (Praha); 1967 Nov; 9(4):353-5. PubMed ID: 4889058
    [No Abstract]   [Full Text] [Related]  

  • 52. A controlled study of the effects of gamfexine in phenothiazine-treated patients.
    Zimmermann RL; Vestre ND; Schiele BC; Curran J
    Curr Ther Res Clin Exp; 1970 Apr; 12(4):230-3. PubMed ID: 4985944
    [No Abstract]   [Full Text] [Related]  

  • 53. Extrapyramidal disorders after prolonged phenothiazine therapy.
    Kennedy PF; Hershon HI; McGuire RJ
    Br J Psychiatry; 1971 May; 118(546):509-18. PubMed ID: 5580366
    [No Abstract]   [Full Text] [Related]  

  • 54. Schizophrenic patients treated with high dose phenothiazine or thioxanthene become deficient in polyunsaturated fatty acids in their thrombocytes.
    Fischer S; Kissling W; Kuss HJ
    Biochem Pharmacol; 1992 Jul; 44(2):317-23. PubMed ID: 1642646
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Experience in the therapy of schizophrenic psychoses with the phenothiazine derivative imiclopazine under the criterion for the neuroleptic threshold].
    Haase HJ; Linden KJ; Boragk J
    Med Welt; 1969 Jul; 28():1565-70. PubMed ID: 5810234
    [No Abstract]   [Full Text] [Related]  

  • 56. Combined therapy in chronic schizophrenics stabilized on phenothiazine tranquilizers and given BL-KR140 or imipramine or placebo concurrently.
    Claghorn JL; Schoolar JC; Ryan JW; Kinross-Wright J
    Curr Ther Res Clin Exp; 1967 Nov; 9(11):576-8. PubMed ID: 4965507
    [No Abstract]   [Full Text] [Related]  

  • 57. [EEG records and effects of phenothiazine treatment in patients with paranoid schizophrenia].
    Ekiert H; Gogol Z; Welbel L; Kazubska M
    Psychiatr Pol; 1977; 11(3):325-33. PubMed ID: 19798
    [No Abstract]   [Full Text] [Related]  

  • 58. Piperacetazine--a new phenothiazine.
    Med Lett Drugs Ther; 1970 Dec; 12(25):103-4. PubMed ID: 5514554
    [No Abstract]   [Full Text] [Related]  

  • 59. [Somatic pathology and causes of death in schizophrenia].
    Volkov VP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(5):14-9. PubMed ID: 19491813
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-acting phenothiazine preparations in the treatment of schizophrenia.
    Kernohan GA
    Br J Psychiatry; 1972 Jan; 120(554):126-7. PubMed ID: 5041515
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.